Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed) | RFA HG 20 015

Opportunity Information: Apply for RFA HG 20 015

The National Institutes of Health (NIH) funding opportunity titled "Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed)" (Funding Opportunity Number RFA-HG-20-015; CFDA 93.172) supports early-stage, high-impact research aimed at dramatically improving how synthetic nucleic acids are made and used. It is an R21 mechanism, which is typically intended for exploratory and developmental projects that may be higher risk but could lead to major advances. Clinical trials are explicitly not allowed under this announcement, so the work should stay focused on technology development, foundational engineering, and preclinical or non-clinical validation rather than testing interventions in human participants.

The core purpose of the FOA is to drive "substantive" advances in synthetic nucleic acid technology, defined in the announcement as no less than a one order of magnitude improvement. In practical terms, applicants are expected to propose approaches that can plausibly deliver about a 10x improvement over current methods in at least one meaningful dimension such as synthesis accuracy and quality, throughput and speed, length/scale of constructs, reliability and reproducibility, functional capabilities of the resulting molecules, or overall efficiency and cost. The overarching goal is not incremental tuning, but step-change progress that makes nucleic acid synthesis and synthetic constructs more capable and more affordable at the same time.

Applicants may respond in several ways, as long as the proposed work targets that kind of order-of-magnitude improvement. Projects can involve developing entirely new end-to-end synthesis platforms or full systems for producing synthetic nucleic acids and constructs. They can also focus on solving key bottlenecks in underlying components that limit performance today, for example chemistry, enzymatic methods, error-correction strategies, assembly methods for longer constructs, automation and miniaturization, or new workflows that reduce hands-on steps and failure rates. Another acceptable path is to take an existing synthesis or construct-generation system and propose a major redesign or breakthrough improvement that credibly reaches the 10x threshold rather than a modest optimization.

A major theme of the announcement is encouragement of approaches that are different from the mainstream methods currently in wide use. The FOA explicitly welcomes exploration of alternative synthesis paradigms, unconventional chemistries, novel enzymatic strategies, new architectures for constructing longer sequences, and other non-traditional routes that could unlock large performance gains. Because of that emphasis, high-risk/high-payoff proposals are considered appropriate, meaning applicants do not necessarily need to present a fully mature technology at the outset, but they do need to make a compelling case that the idea is innovative, technically grounded, and capable of producing transformative improvements if successful.

Eligibility is broad and includes many organization types. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (other than higher education institutions); for-profit organizations (other than small businesses); and small businesses. The announcement also highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, U.S. territories or possessions, and even non-U.S. entities (foreign organizations) and regional organizations, reflecting an intent to attract a wide range of capable performers.

From an administrative standpoint, this is a discretionary grant opportunity run by NIH, categorized under the health funding activity area. The original closing date listed for the opportunity was 2022-02-04, and the opportunity was created on 2020-03-19. While the provided source text does not specify an award ceiling or the expected number of awards, the central takeaway for prospective applicants is that NIH is looking for bold, technically credible R21 projects that can deliver major measurable gains in synthetic nucleic acid synthesis and synthetic constructs, while keeping an eye on real-world practicality such as improved efficiency and reduced costs.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.172.
• This funding opportunity was created on 2020-03-19.
• Applicants must submit their applications by 2022-02-04. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA HG 20 015

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: